ALLMedicine™ Mantle Cell Lymphoma Center

May 7th, 2021 - Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of att...

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

Apr 27th, 2021 - Combining synthetic biology with adoptive T cell transfer has led to promising advances in the treatment of relapsed refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL)....

Apr 22nd, 2021 - Transcriptome differences between Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), which are all derived from B cell, remained unclear. This study aimed to construct lymphoma-specific diagnostic model...

Apr 19th, 2021 - Chimeric antigen receptor (CAR) T cells have emerged as a powerful therapeutic modality for cancer. Following encouraging clinical results, autologous anti-CD19 CAR-T cells first secured regulatory approval from the U.S. Food and Drug Administrati...

Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...

May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial...

Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our f...

May 16th, 2018 - Guideline for the management of mantle cell lymphoma.|2018|McKay P,Leach M,Jackson B,Robinson S,Rule S,|therapeutic use,prevention & control,methods,pathology,therapy,

Sep 8th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

May 7th, 2021 - Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of att...

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

Apr 27th, 2021 - Combining synthetic biology with adoptive T cell transfer has led to promising advances in the treatment of relapsed refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL)....

Apr 22nd, 2021 - Transcriptome differences between Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), which are all derived from B cell, remained unclear. This study aimed to construct lymphoma-specific diagnostic model...

Apr 19th, 2021 - Chimeric antigen receptor (CAR) T cells have emerged as a powerful therapeutic modality for cancer. Following encouraging clinical results, autologous anti-CD19 CAR-T cells first secured regulatory approval from the U.S. Food and Drug Administrati...

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

Sep 9th, 2020 - Dr Eduardo Sotomayor Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and which should receive aggressive t...